Why insider trading matters?

If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.

- Klaus Gugler, Economist
SpringWorks Therapeutics, Inc. (SWTX)
Sector: Healthcare; Industry: Biotechnology

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase IIb clinical trial for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in preclinical trials for the treatment of RRMM. SpringWorks Therapeutics, Inc. has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib, as well as medicines; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-06-10 ORBIMED ADVISORS LLC 10%-Owner Sell 30,852 $85.09 $2,625,197 No
2021-06-09 ORBIMED ADVISORS LLC 10%-Owner Sell 48,053 $85.36 $4,101,908 No
2021-03-01 ORBIMED ADVISORS LLC 10%-Owner Sell 1,220,000 $83.19 $101,491,800 No
2019-09-17 ORBIMED ADVISORS LLC 10%-Owner Buy 275,000 $18.00 $4,950,000 Yes

Insider Smart

Delta Airlines (DAL) - From an insider's perspective: airlines are the first ones to go under due to the pandemic. A lot of concerns were raised on possible bankruptcy especially amid by the dump from Buffett. However, insiders of Delta were bold enough to buy when Buffett was fear. And Delta is the only airline bought by insiders post-Buffett-dump.

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.